Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Multiple Myeloma 188Lymphoma, Mantle-Cell 34Neoplasms, Plasma Cell 32Lymphoma 32Recurrence 26Lymphoma, Follicular 20Waldenstrom Macroglobulinemia 18Lymphoma, Non-Hodgkin 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Lymphoma, B-Cell, Marginal Zone 13Carcinoma, Non-Small-Cell Lung 13Immunoglobulin Light-chain Amyloidosis 10Neoplasms 9Leukemia, Myeloid, Acute 9Lymphoma, B-Cell 8Renal Insufficiency 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia 7Hodgkin Disease 6Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Prostatic Neoplasms 4Myelodysplastic Syndromes 4Kidney Neoplasms 4Carcinoma, Renal Cell 4Breast Neoplasms 4Brain Neoplasms 4Amyloidosis 4Stomach Neoplasms 3

Interventions

Magnetic Resonance Spectroscopy 8Iodine-131 5trametinib 3lenvatinib 3Thyrotropin Alfa 3Sunitinib 3Specimen Handling 3Sorafenib 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3selpercatinib 2dabrafenib 2cabozantinib 2X-Rays 2Vemurafenib 2Radiotherapy 2Everolimus 2AZD 6244 2vandetanib 1tremelimumab 1tovorafenib 1tanespimycin 1spartalizumab 1sargramostim 1romidepsin 1pembrolizumab 1omipalisib 1motesanib diphosphate 1entrectinib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Cancer, Papillary × Bortezomib × Clear all
NCT00104871 2018-12-19

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

National Cancer Institute (NCI)

Phase 2 Completed
24 enrolled 6 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡